LifeArc joins Infection Innovation Consortium to help tackle infectious diseases

LifeArc are partnering with Liverpool School of Tropical Medicine (LSTM) to launch a new development fund to…

New Alzheimer’s treatment ‘lecanemab’ approved for use in the US

LifeArc played an instrumental role in the drug’s development through our antibody humanisation work.

LifeArc and DEBRA Austria launch £2.5m funding call for repurposing therapies for Epidermolysis Bullosa

Joint initiative part of LifeArc’s £100 million Translational Challenge to help address rare disease translational science.

Catriona Crombie talks to Rare Revolution about LifeArc’s investment of more than £100 million into rare disease research by 2030

Catriona discusses why LifeArc is well placed to help overcome some of the obstacles in rare disease research

Groundbreaking new £100m LifeArc programme aims to improve the lives of people living with a rare disease

Brings together the world-leading expertise of Health Data Research UK, University of Edinburgh, LifeArc, Eisai and Gates Ventures

New UK-based research project brings together world-leading institutions to transform care for people living with dementia

Brings together the world-leading expertise of Health Data Research UK, University of Edinburgh, LifeArc, Eisai and Gates Ventures

LifeArc strengthens Board of Trustees with new appointments

Dr Terri Cooper, Dr Sameer Mistry and Dr Rima Makarem join LifeArc's Board of Trustees as Non-Executive Directors.

How LifeArc’s Neurodegeneration Translational Challenge is leading the charge against Motor Neurone Disease

June 21st is Global MND Awareness Day, a day to raise worldwide awareness of MND (Motor Neurone Disease) and to stand in solidarity with the MND/ALS community.

New programme to move potential MND drugs into clinical trials faster

EXPERTS-ALS to screen candidate drugs at scale and identify those that should be fast-tracked to larger clinical trials